| Literature DB >> 25897223 |
Muthu Vignesh Vellayappan1, Arunpandian Balaji1, Aruna Priyadarshini Subramanian1, Agnes Aruna John1, Saravana Kumar Jaganathan1, Selvakumar Murugesan2, Eko Supriyanto1, Mustafa Yusof1.
Abstract
Cardiovascular disease is the leading cause of death across the globe. The use of synthetic materials is indispensable in the treatment of cardiovascular disease. Major drawbacks related to the use of biomaterials are their mechanical properties and biocompatibility, and these have to be circumvented before promoting the material to the market or clinical setting. Revolutionary advancements in nanotechnology have introduced a novel class of materials called nanocomposites which have superior properties for biomedical applications. Recently, there has been a widespread recognition of the nanocomposites utilizing polyhedral oligomeric silsesquioxane, bacterial cellulose, silk fibroin, iron oxide magnetic nanoparticles, and carbon nanotubes in cardiovascular grafts and stents. The unique characteristics of these nanocomposites have led to the development of a wide range of nanostructured copolymers with appreciably enhanced properties, such as improved mechanical, chemical, and physical characteristics suitable for cardiovascular implants. The incorporation of advanced nanocomposite materials in cardiovascular grafts and stents improves hemocompatibility, enhances antithrombogenicity, improves mechanical and surface properties, and decreases the microbial response to the cardiovascular implants. A thorough attempt is made to summarize the various applications of nanocomposites for cardiovascular graft and stent applications. This review will highlight the recent advances in nanocomposites and also address the need of future research in promoting nanocomposites as plausible candidates in a campaign against cardiovascular disease.Entities:
Keywords: cardiovascular biomaterials; hemocompatibility; nanocomposites; nanoparticles; stents; vascular grafts
Mesh:
Year: 2015 PMID: 25897223 PMCID: PMC4396644 DOI: 10.2147/IJN.S80121
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Categories of synthetic nanocomposites.
Figure 2Properties improved by the use of nanocomposites for cardiovascular grafts.
Figure 3Properties improved by the use of nanocomposites for cardiovascular stent.
Figure 4Properties enhanced by nanocomposites for cardiovascular graft and stent application.
Nanocomposites used for cardiovascular grafts and their key properties
| Serial number | Nanocomposite | Property enhanced by nanocomposites | References |
|---|---|---|---|
| 1 | Bacterial cellulose (BC) with polyvinyl alcohol (PVA) | 1. Improved blood compatibility | |
| 2. Elevated elastic modulus and degree of crystallinity | |||
| 2 | Multiwalled carbon nanotubes-polyurethane nanocomposite (MWCNT-PU) | 1. Reduced platelet adhesion and activation | |
| 2. Reduced hemolysis index (HI) | |||
| 3 | Carbon nanotube-polycaprolactone (CNT-PCL) | 1. Cardiac progenitor cells (CPCs) from murine heart proliferated better on the thiophene-conjugated carbon nanotubes-polycaprolactone (TCNT-PCL) | |
| 2. Elastic modulus improved with the inclusion of CNT (concentration up to 12.5 mg/mL) in PCL | |||
| 3. Improved tensile strength | |||
| 4. Increased tensile strength and elastic modulus | |||
| 4 | Alginate matrix and MWCNTs | 1. Improved tensile strength | |
| 5 | Polyhedral oligomeric silsesquioxane-poly(carbonate-urea)urethane (POSS-PCU) with nanosilver particles (NS) | 1. Improved antithrombogenic properties | |
| 6 | POSS-PCU | 1. Enhance the cell adhesion property | |
| 7 | POSS-PCU with endothelial cells (EC) pre-seeding | 1. Improvement of the cell adhesion | |
| 8 | POSS-PCU with biofunctional peptide arginine-glycine-aspartic acid (RGD) | 1. Improved quality of cell adhesion and proliferation | |
| 9 | POSS-PCU with selective biofunctionalization | 1. Improve the affinity of the surface to ECs and reduce attachment and proliferation of smooth cells | |
| 10 | POSS-PCU subjected to plasma surface modification | 1. Increased adhesion, coverage, and growth of human umbilical vein endothelial cells | |
| 11 | Carbon nanofibers (CNF) with poly(lactic- | 1. Cardiomyocyte growth promoted | |
| 2. Tensile strength of the polymer increased | |||
| 12 | Silk fibroin (SF) with hydroxyapatite (HA) | 1. Improved biomechanical properties | 70 |
| 13 | BC nanocomposites with PVA hydrogels | 1. Longer relaxation time | |
| 2. Faster relaxation rates and a lower relaxed stress |
Nanocomposites used for cardiovascular stents application and their key properties
| Serial number | Nanocomposite | Key properties | References |
|---|---|---|---|
| 1 | Polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) with anti-CD34 antibodies | 1. Improvement in capture of circulating endothelial progenitor cells (EPC) | |
| 2. Decrease in hydrophobicity | |||
| 3. Has only a negligible effect on coagulation kinetics | |||
| 2 | POSS-PCU with carboxylic functional groups and extra cellular matrix (ECM) proteins | 1. Grafting controlled amounts of carboxylic functional groups on POSS-PCU can be done | |
| 3 | Iron oxide magnetic nanoparticles (MNPs) with chitosan (CS) and polyethylene glycol (PEG) followed by kojic acid (KA) loading | 1. Release profile of KA followed pseudo second-order kinetic model | |
| 2. All formulations consisted of highly crystalline, pure magnetite Fe3O4 | |||
| 3. Nanocomposites are superparamagnetic and possess saturation magnetization of 8.1 and 26.4 emu/g | |||
| 4 | MNP with CS and KA | 1. MNPs had no antimicrobial effect on the microorganisms tested | |
| 2. KA-CS-MNPs and KA-PEG-MNPs nanocomposites displayed minimal to no antimicrobial activity | |||
| 5 | MNP with CS Nystatin (Nyst-CS-MNP) | 1. Improved antifungal activity | |
| 6 | Eudragit S-100 (ES) with combination of hexafluoro-2-propanol (HFIP), poly(lactic- | 2. Improved endothelialization at the implanted sites | |
| 7 | Carbon nanofibers (CNF) PLGA | 1. Cardiomyocytes were able to grow and express important biomarkers | |
| 2. Adhesion and proliferation of cells was improved | |||
| 8 | POSS-PCU with CD34 antibodies | 1. CD34-POSS-PCU capable of supporting growth and proliferation of HUVEC cells | |
| 2. Stable even under flow conditions |
Abbreviations: HUVEC, human umbilical vein endothelial cells; PLA, polylactic acid.